SurModics Inc. (NASDAQ:SRDX)’s share price reached a new 52-week high on Monday . The company traded as high as $29.94 and last traded at $29.53, with a volume of 29,215 shares. The stock had previously closed at $29.04.

SRDX has been the subject of a number of analyst reports. Zacks Investment Research raised SurModics from a “hold” rating to a “strong-buy” rating and set a $27.00 price target for the company in a report on Wednesday, May 4th. Barrington Research boosted their price objective on SurModics from $27.00 to $30.00 and gave the stock an “outperform” rating in a research note on Tuesday, May 3rd. Finally, TheStreet upgraded SurModics from a “hold” rating to a “buy” rating in a research note on Tuesday, April 26th.

The company has a 50 day moving average of $26.30 and a 200-day moving average of $22.09. The stock has a market capitalization of $384.57 million and a P/E ratio of 44.07.

SurModics (NASDAQ:SRDX) last released its quarterly earnings results on Thursday, July 28th. The company reported $0.37 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.12 by $0.25. The company had revenue of $19.97 million for the quarter, compared to analysts’ expectations of $16.31 million. The business’s quarterly revenue was up 25.6% compared to the same quarter last year. During the same period in the prior year, the business earned $0.30 EPS. Equities research analysts anticipate that SurModics Inc. will post $1.04 earnings per share for the current year.

In related news, VP Charles W. Olson sold 9,936 shares of the firm’s stock in a transaction dated Wednesday, August 17th. The stock was sold at an average price of $28.98, for a total transaction of $287,945.28. Following the transaction, the vice president now owns 33,098 shares of the company’s stock, valued at $959,180.04. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Susan E. Knight sold 1,548 shares of the firm’s stock in a transaction dated Monday, August 15th. The stock was sold at an average price of $28.64, for a total value of $44,334.72. The disclosure for this sale can be found here.

SurModics, Inc is a provider of surface modification and in vitro diagnostic technologies to the healthcare industry. The Company operates through two segments: Medical Device and In Vitro Diagnostics. The Company is focused on to transform its medical device business from being a provider of coating technologies to offering whole product solutions to medical device customers.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.